Construction and expression of a recombinant eukaryotic expression plasmid containing the preS1-preS2-S genes of hepatitis B virus and the granulocyte-macrophage colony stimulating factor gene: A study of its immunomodulatory effects

JUN-YUAN GONG*, XIN LIU*, YAN DONG, TIAN-HONG ZHOU and JUN-WU LI

Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, P.R. China

Received August 18, 2012; Accepted November 6, 2012

DOI: 10.3892/br.2012.47

Abstract. A total of 10-20% of the population remains unresponsive or weakly responsive to hepatitis B vaccine, which is composed of hepatitis B surface antigen HBsAg (S protein). Therefore, it is necessary to develop a hepatitis B vaccine with a better penetrating and responsive rate. In the present study, a plasmid pVAX1-L-GM was constructed and its immunomodulatory effect of as hepatitis B virus (HBV) DNA vaccine was analyzed through the immunization of BALB/c mice. Immune responses were measured after immunization by anti-HBsAg, proliferation of splenocytes, the number of CD4+ and CD8+ molecules, CTL cytotoxicity, cytokines of IFN-γ and IL-2 secretion assays. Following the immunization, mice in the pVAX1-L-GM group produced antibody 2 weeks earlier compared to the control plasmid pVAX1 and pVAX1HBsAg groups and antibody levels showed significant differences. Enhanced HBsAg‑specific splenocyte proliferation as well as specific cytotoxic activities of splenic CTLs were also detected. Furthermore, pVAX1-L-GM plasmid increased the number of CD4+ and CD8+ molecules on the surface of the spleen T cell and the level of IFN-γ, IL-2 secretion. pVAX1-L-GM induced a specific immune response in mice and enhanced the immune effect. Thus, a foundation was laid for developing immunogenicity of a better prevention and treatment of HBV via a hepatitis B vaccine.

Introduction

Hepatitis B virus (HBV) infection is one of the most significant public health problems worldwide. Approximately one-third of the world's 6.0 billion population is estimated to be infected with HBV (1), including 350-400 million chronic carriers of this virus (2). The HBV vaccine applied at present is primarily composed of HBsAg (S protein) expressed by Chinese hamster ovary (CHO) cells and beer yeast. A total of 10-20% of the population is known to be unresponsive or weakly responsive to the HBV vaccine or even not to produce antibodies at all (3,4). Vaccination is crucial in the prevention of HBV infection and there are no specific therapies to manage it. Therefore, it is crucial to develop a hepatitis B vaccine with a better penetrating and responsive rate.

Hepatitis B vaccine made by recombinant DNA techniques has the same degree of safety as the recombinant subunit vaccine and the same efficacy to induce immune response as live attenuated vaccine. It is relatively simple to clone and is a purified DNA with no need for a synthetic protein in vitro, and can sustain long‑term immune efficacy (5). The recombinant DNA vaccine is also relatively cost-effective and convenient to transport and preserve, thus it is a promising approach for the vaccine development. HBV DNA vaccination may induce the CD8+ T cell as well as dominant Th1 phenotype among the splenic lymphocytes, to elicit strong CTL and protective antibody levels (6).

To overcome traditional HBsAg vaccine immunogenicity defects, HBV large envelope protein (L protein) was selected as a dominant antigen, while granulocyte-macrophage colony stimulating factor (GM-CSF) acted as an immune adjuvant to enforce antibody response and construct an eukaryotic expression plasmid pVAX1-L-GM containing preS1, preS2 and S genes of the L protein and immune adjuvant GM-CSF. After the successful expression of the vaccine into the L-02 cell line, immune responses were stimulated in mice to lay a foundation for the development of a novel type of hepatitis B DNA vaccine.

Materials and methods

Ethics. The present study was conducted in the Department of Microbiology and Immunology of the Medical College of the Jinan University (Guangzhou, China). The Ethics Committee of The First Affiliated Hospital of the Jinan University (Guangzhou, China) approved the animal procedures and the experimental protocol.
Construction and identification of recombinant plasmid. Based on the CDS sequence of the preS1-preS2-S gene (GL157091234), the primers 5′-CAGCTAGCATGG GAGGTTGTCCTTCCAA-3′ (upstream) (NheI) (Takara Bio Inc., Otsu, Japan) and 5′-GGCGGAAGCTTAATGTATACCC AAAGAC-3′ (downstream) (HindIII) with appropriate restriction endonuclease sites. Hepatitis B DNA extraction was obtained from the hepatitis B surface antigen-positive serum (The First Affiliated Hospital of the Jinan University) using phenol/chloroform extraction methods and used as a template to amplify HBV preS1 preS2 S region. The coding sequences of these GM-CSF fragments were synthesized using PCR from pORF-GM-CSF using specific primers, upstream: 5′-CCA AGCTTGTTGCGGATGGAAAGCGCGTGGCGGAAGCG CGCGGTGGCAGCTTGCTGCAGAGCCTGCTGTC-3′ (HindIII and Linker), downstream: 5′-CGGAATTCTCAGCATGG TGGACTGGCTC-3′ (EcoRI), and cloned into pVAX1 using the standard cloning techniques. PCR and restriction endonuclease assay were used to screen and identify positive clones. DNA sequencing analysis (Sangon Biological Engineering and Technology and Service Company, Shanghai, China) of the recombinant pVAX1-L-GM identified the successful constructions of recombinant plasmid pVAX1-L-GM.

Cell transfection. L-02 cells were digested with 0.25% trypsin and diluted to 2×10⁴ cells/ml and plated to 6-well plates with 2 ml medium per well. Then, when cells were 70-80% confluent, 4 µg purified plasmid were transfected into the prepared cells using 8 µl Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).

Immunocytochemical staining. Non-transfected cells were considered as the blank, while pVAX1-transfected cells as the negative comparison. Immunocytochemical staining was performed according to the manufacturer's instructions (Boster Biological Technology, Ltd., Wuhan, China), and mouse anti-HBsAg antibody was used as the primary antibody.

Western blot analysis. Western blot analysis of fusion proteins was performed according to the standard procedure. The purified protein was separated on 12% SDS–PAGE and transferred to nitrocellulose membrane. Anti-HBsAg mAb antibody (Beijing Biosynthesis Biotechnology Co., Beijing, China) at a dilution of 1:1000 or Anti-GM-CSF mAb was used as the primary antibody to detect the presence of protein. Blots were developed using the ECL (Thermo Fisher Scientific, Inc., Rockford, IL, USA) method with HRP-labeled rabbit anti-mouse IgG at a dilution of 1:5000.

ELISA assay protein levels of GM-CSF. Double-antibody sandwich ELISA (DAS-ELISA) was used to detect the GM-CSF protein level according to the manufacturer's instructions (R&D Inc., Minneapolis, MN, USA). The results were presented as the mean ± standard deviation (SD), and statistically significant differences between values were analyzed using the SPSS 13.0 software. P<0.05 was considered to indicate a statistically significant difference.

Animal immunization. Female BALB/c mice (n=30; 6–8 weeks old) were purchased from the Experimental Animal Center of the Jinan University (Guangzhou, China) and divided equally into 3 groups (n=10/group). Mice were immunized intramuscularly individually with pVAX1-L-GM, pVAX1 and pVAX1HBsAg. The mice were then injected with a dose of 100 µg/100 µl plasmid pVAX1-L-GM, pVAX1 and pVAX1HBsAg, 3 times every second week. Blood was obtained from the tail each week after immunization. The spleens of each mouse in the vaccinated groups were removed aseptically at week 13 after the first immunization.

Detection of specific anti-HBsAb antibodies using the ELISA test. After the first-immunization, serum was collected every week using the tail vein bleeding method. Absorbance at 450 nm was measured in a microplate reader, according to the manufacturer's instruction of the Mouse HBsAb ELISA kit (Wuhan ELAab Science Co., Ltd., Wuhan, China). Levels of serum antibody in immunized mice were monitored for 12 weeks.

Proliferation of splenocytes. Lymphocyte proliferation of immunized mice was measured by MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]. At week 13 following the first immunization, mice were sacrificed, their spleens were aseptically removed and splenocytes were prepared as single-cell suspensions. The cells were cultured in triplicate using 96-well round-bottom plates at 2×10⁵ cells per well. RPMI-1640 (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (FCS) was added to each well, and stimulated with HBsAg at a final concentration of 10 µg/ml. Lymphocytes stimulated with the medium alone were used as the negative control. The cells were incubated for 48 h at 37°C in a humid atmosphere of 5% CO₂, then 20 ml of MTT (5 mg/ml) (Sigma-Aldrich, Shanghai, China) was added to each well. Following additional incubation for 4 h, the supernatant was carefully aspirated and 200 µl of dimethylsulfoxide (DMSO) was added into each well and absorbance of the soluble formazan was measured at 570 nm using an automatic microplate reader (Bio-Rad, Hercules, CA, USA).

Cytotoxicity assay. Splenocytes obtained from mice at week 13, following the first immunization were cultured in 24-well plates with complete culture RPMI-1640 medium [with 10% FBS, 50 µM 2-mercaptoethanol, 10 mM HEPES, 2 mM L-glutamine, 100 units of penicillin per ml and 100 µg of streptomycin per ml]. Complete culture RPMI-1640 medium was used containing 5 µg/ml Concanavalin A (Dingguo Biotech, Beijing, China) and 10 U/ml of IL-2 (Pepro Tech, London, UK) to culture splenocytes in vitro for 2 days as the effector. The stimulator cells, harvested from naïve mice, were pulsed with the final concentration of 20 µg/ml of HBV-specific peptide for 4 h at 37°C in 5% CO₂, and were then treated with 80 µg/ml mitomycin C for another 2 h. The cells were washed extensively with RPMI-1640 medium. The effector cells (4×10⁷ cells) were incubated with stimulator cells at an effector-stimulator ratio of 10:1 for 7 days in culture medium containing 10 U/ml recombinant IL-2 (Peprotech, Rocky Hill, NJ, USA) at 37°C in 5% CO₂. The target cells were prepared by P815 cells (mouse mastocytoma cell line, Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences) pulsed with HBV-specific peptide for 4 h at 37°C in
5% CO₂. The cytotoxic activity was tested by non-radioactive LDH release assay. The assays were performed in triplicate with 1x10⁴ target cells/well incubated with effector cells at various effector cell/target cell (E:T) ratios of 100:1, 50:1, 25:1 and 12.5:1 in 96-well round-bottom plates, according to the Non-Radioactive Cytotoxicity Assay Kit (Promega, Madison, WI, USA). The absorbance values from the supernatants were recorded at 490 nm using an ELISA microplate reader.

Analysis of the molecules of CD4⁺ and CD8⁺ on the surface of T cell. At week 13 following immunization, the mice were sacrificed and their spleens were removed aseptically. Phosphate-buffered saline (PBS) buffer (0.1 mmol/l) was used to wash the spleen cells and cell suspension was collected. The CD4⁺/CD8⁺ detection kit (Beckman Coulter, Inc., Brea, CA, USA) required the volume of 100 µl of each sample intake, in order to detect the number of CD4⁺, CD8⁺ molecules on the surface of spleen T cells using the Epics XL flow cytometry (Beckman Coulter, Miami, FL, USA).

Cytokines of IFN-γ and IL-2 secretion assays. The splenocytes of immunized mice were cultured following the same procedure in the proliferation assays for 72 h. Following incubation, the supernatant from each well was removed for evaluation of secreted IFN-γ and IL-2 levels using ELISA. The concentrations of IFN-γ and IL-2 in the culture supernatant were measured using murine cytokine ELISA kits (R&D Systems, Minneapolis, MN, USA). The limit of the detection was 2 pg/ml.

Statistical analysis of data. Measurement data show the mean ± SD. The statistical software SPSS was used to perform statistical analysis. Differences between groups were analyzed using stochastic analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

In vitro expression of the recombinant plasmid. To determine whether or not the recombinant plasmid pVAX1-L-GM was expressed in vitro, L-02 cells were transiently transfected with pVAX1-L-GM or pVAX1 and their expression at a protein level was detected using western blot analysis and ELISA assay, respectively. Western blot analysis indicated a protein level of ~64 kDa, as expected (Figs. 1 and 2). Expression values of GM-CSF proteins in the pVAX1 control group were 1.382±0.081 pg/ml and 1.382±0.081 pg/ml (mean ± SD, n=3). While the expression values of the GM-CSF proteins of the pVAX1-L-GM-transfected group were 153.073±4.20 and 193.124±3.943 pg/ml, compared to the negative control groups (cell control and pVAX1), the results were considered statistically significant (P<0.05) (Fig. 3).

Detection of specific anti-HBsAb antibodies using ELISA. To assess the effect of the pVAX1-L-GM DNA vaccine on the humoral responses in mice, blood samples were collected using the tail vein bleeding method each week following the first immunization, and the sera were isolated. The presence of anti-HBsAg-specific antibodies in sera was analyzed by ELISA. Specific antibody response was detectable in the pVAX1-L-GM and pVAX1HBsAg groups (Fig. 4). Statistical analysis of antibody levels of pVAX1-L-GM and pVAX1HBsAg groups was performed and an enhanced antibody response was observed in the pVAX1-L-GM group, and the difference was statistically significant (P<0.05). The pVAX1-L-GM group produced antibody 2 weeks earlier than the control plasmid pVAX1 and pVAX1HBsAg groups.

Proliferation of splenocytes. To determine whether or not the pVAX1-L-GM DNA vaccine influenced cell-mediated immunity, a single-cell suspension of lymphocytes was prepared from immunized mice at week 13 after immunization. As shown in Fig. 5, mice immunized with pVAX1-L-GM elicited the highest level of splenocyte T-cell proliferation compared to the pVAX1HBsAg and pVAX1 groups (P<0.05).
Cytotoxicity assay. In the protection against or eradication of viruses or other intracellular pathogens, specific cytotoxic responses have been previously demonstrated to be a key factor. To analyze the ability of recombinant pVAX1-L-GM to enhance the HBsAg-specific CTL response, splenic cells, derived from the immunized mice 13 weeks after immunization, were restimulated specifically by naive mice splenocytes pulsed with HBsAg-specific peptides in vitro for 7 days. P815 cells pulsed with HBsAg-specific peptides were used as target cells. The cytotoxic activity was tested using non-radioactive LDH release assay and the specific lysis rates are shown in Fig. 6. HBsAg-specific CTL was detectable in the mice immunized with the HBV DNA vaccine pVAX1-L-GM plasmids compared to the pVAX1HBsAg or pVAX1 groups at the E/T ratio of 100:1 (P<0.05). The specific CTL activities increased significantly in the pVAX1-L-GM and pVAX1HBsAg groups compared to the pVAX1 group, while the strongest CTL response was detected at the E/T ratio of 100:1 (P<0.01). The results demonstrated that cellular immunity was markedly enhanced by pVAX1-L-GM DNA and pVAX1HBsAg DNA vaccine plasmids.

Analysis of the molecules of CD4⁺, CD8⁺ on the surface of T cell. To evaluate the subsets of T cells, total T cells were isolated at week 13 following immunization and re-stimulated in culture with HBsAg. These cells were then analyzed using FACS with a gate set on CD4⁺ and CD8⁺ T cells. As shown in Fig. 7, the number of CD4⁺ and CD8⁺ T cells produced by the pVAX1-L-GM group was higher compared to the pVAX1HBsAg group, and the difference was statistically significant (P<0.05), indicating that the GM-CSF gene enhanced cell immune function.

Cytokines of IFN-γ and IL-2 secretion assays. We quantified the production of the cytokines IFN-γ and IL-2 released from splenocytes from immunized mice re-stimulated with HBsAg in vitro. Mice immunized with DNA vaccine pVAX1-L-GM elicited a significant enhancement of IFN-γ and IL-2 production, even significantly higher compared to the pVAX1HBsAg group.
was used as an immune adjuvant, for studies of the γ-fusion gene. The immune effect of preS1-γ, and the plate was able to increase antibody levels in subjects of immune activity of CTL and NK, thereby strengthening the immune function of antigen-presenting cells and enhance the cytotoxicity of HBV and protect against HBV infection gorillas (7–9).

In this study, the L protein was used as an antigen. Compared to the gene of the S protein, the gene of L protein has more T- and B-cell epitopes, and that anti-preSI serum is able to neutralize the toxicity of HBV and protect against HBV infection in vitro, and the plate was incubated at 37°C for 60 h with 5% CO2, IFN-γ and the IL-2 concentration of the lymphocyte secreted into the medium was measured using an ELISA kit, according to the manufacturer’s instructions. *P<0.05 compared to the pVAX1HBsAg group. **P<0.05 compared to the pVAX1 control group.

**Discussion**

In this study, the L protein was used as an antigen. Compared to the gene of the S protein, the gene of L protein has more preSI and preS2 gene. Previous studies demonstrated that the preSI (21-47aa) is the liver cell receptor binding site, which binds the HBV into the host cell membrane. Previous studies have also demonstrated that the preSI peptide has several T- and B-cell epitopes, and that anti-preSI serum is able to neutralize the toxicity of HBV and protect against HBV infection gorillas (7–9). PreS2 (120-145aa) sequence also contains multiple epitopes which are able to neutralize the virus. It is able to mediate HBV adhesion and the invasion of liver cells, and with strong immunogenicity, is able to induce the generation of neutralizing antibodies and protective immunity. Containing the specific T and B lymphocytes binding site, it is able to break the body immune tolerance of existing HBsAg vaccine (10-12).

There has been an increasing demand for gene adjuvant therapy both in the treatment and prevention of HBV in recent years, thus GM-CSF as a preponderant adjuvant is important in activating endothelialocytes and macrophagocytes through various mechanisms. It can also regulate the amount and function of antigen-presenting cells and enhance the cytotoxicity of CTL and NK, thereby strengthening the immune level of the hepatitis B vaccine. Several clinical trials showed that GM-CSF is able to increase antibody levels in subjects in a rapid, effective and constant manner (13-15). Therefore, GM-CSF was used as an immune adjuvant, for studies of gene adjuvant in the field of DNA vaccine immunopotency improvement.

In this study, we used vector-pVAX1, which was approved by the Food and Drug Administration (FDA) and could be used in the late stages of human disease, to clone a recombinant plasmid which containing the gene of the L protein and the GM-CSF gene, through Linker to connect the fusion gene consisting of glycine (G) and serine (S) to five peptides (16). Thus, the recombinant plasmid was transfected into L-02 cells using liposome transfection methods, confirming the successful construction of pVAX1-L-GM by restriction enzyme digestion and sequencing, and also confirming the stable expression of fusion protein using western blot analysis and ELISA.

To determine whether or not the pVAX1-L-GM plasmid has any effect on the cell and humoral immune responses in BALB/c mice, three groups of mice were immunized in the study with negative control plasmid (pVAX1 group), positive control plasmid (pVAX1HBsAg group) and recombinant plasmid (pVAX1-L-GM group). The level of antibody was then detected and the results showed that the antibody level of the experimental pVAX1-L-GM group was higher compared to the empty vector pVAX1 and positive control pVAX1 HBsAg groups. The difference was statistically significant (P<0.05). Additionally, studies have demonstrated that the presence of antibodies in the pVAX1-L-GM group was recorded two weeks earlier compared to the pVAX1HBsAg group. Splenocytes from mice in the three groups were evaluated for antigen-specific proliferation as well as the CTL component of immune response by the specific killing of syngeneic target cells pulsed with a recognized CTL epitope peptide. The number of CD4+ and CD8+ molecules on the surface of spleen T cells and the level of IFN-γ and IL-2 was also detected. The strongest HBsAg-specific proliferative activity in the pVAX1-L-GM group was in concordance with the highest level of CTL activity and CD4+, CD8+ molecules and IFN-γ, IL-2 production in the two groups. The level of CD8+ on cytotoxic T lymphocyte was increased, indicating that cell immunity was significantly enhanced after immunization by the fusion L-GM gene. The results indicated that the plasmid pVAX1-L-GM is able to enhance the specific cell and humoral immune responses in mice.

Possible for these results are that the L protein has several advantageous features of its antigens, compared to the commercially available hepatitis B HBsAg vaccine whose component contains only S antigen. GM-CSF as an adjuvant is able to stimulate the activation of antigen-presenting cells, promote the secretion of IL-2 and the proliferation of CD4+ and CD8+ cells, thus it is likely to be important in enhancing the DNA vaccine induction of humoral and cell immune responses.

In summary, the results suggest that L protein stimulated the cell and humoral immune response following immunization of mice with L-GM fusion gene. The immune effect of vaccine pVAX1-L-GM was superior to that of pVAX1HBsAg vaccine since cell immunity is considered to be the most essential host immune response to eradicating the virus.
Therefore, this study provided a novel method to enhance the effect of hepatitis B DNA vaccine, as well as an effective means to develop hepatitis B DNA vaccine as a prevention and treatment vaccine. Additional investigations into the immune protection of the vaccine may have better prospects.

Acknowledgements

The present study was supported by the Research Fund of the Science and Technology Plan of Guangdong Province (no. A20101006-2006) and the Major National Science and Technology (S&T) Special Projects (no. 2008ZX10002-009).

References